News

Alumis reported positive topline results from two Phase 3 trials of envudeucitinib in moderate-to-severe plaque psoriasis, with approximately 65%...

Gilead has exercised its option to license Assembly Biosciences’ helicase-primase inhibitor program for recurrent genital herpes, taking over ABI-5366...

SELLAS Life Sciences signaled a catalyst-heavy 2026 in acute myeloid leukemia. The company is approaching the final overall survival...

Humacyte has entered a registered direct offering to sell 25 million shares of common stock for expected gross proceeds...

Pelthos Therapeutics posted its first meaningful commercial snapshot as a pediatric dermatology-focused player, reporting $16.2 million in net product...

Mesoblast will host its inaugural R&D Day on April 8, 2026 in New York, with a live webcast detailing...

Artelo Biosciences has entered a definitive investigator-initiated study agreement with Belfast Health and Social Care Trust to evaluate ART27.13,...

Harrow will present three abstracts at the ASCRS 2026 Annual Meeting in Washington, D.C., spotlighting new data for Vevye...

Longeveron outlined a pivotal year ahead, confirming it remains on track to deliver top-line data in the third quarter...

Trevi Therapeutics has secured end-of-Phase 2 alignment with FDA for Haduvio (oral nalbuphine ER) in idiopathic pulmonary fibrosis (IPF)-related...